874 related articles for article (PubMed ID: 32248000)
1. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target.
Gambardella V; Castillo J; Tarazona N; Gimeno-Valiente F; Martínez-Ciarpaglini C; Cabeza-Segura M; Roselló S; Roda D; Huerta M; Cervantes A; Fleitas T
Cancer Treat Rev; 2020 Jun; 86():102015. PubMed ID: 32248000
[TBL] [Abstract][Full Text] [Related]
2. The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review.
Bos J; Groen-van Schooten TS; Brugman CP; Jamaludin FS; van Laarhoven HWM; Derks S
Cancer Treat Rev; 2024 Jun; 127():102737. PubMed ID: 38669788
[TBL] [Abstract][Full Text] [Related]
3. A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer.
Seif F; Sharifi L; Khoshmirsafa M; Mojibi Y; Mohsenzadegan M
Curr Drug Targets; 2019; 20(7):789-798. PubMed ID: 30674255
[TBL] [Abstract][Full Text] [Related]
4. Blockade of DC-SIGN
Hu B; Wang Z; Zeng H; Qi Y; Chen Y; Wang T; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Cancer Res; 2020 Apr; 80(8):1707-1719. PubMed ID: 32060149
[TBL] [Abstract][Full Text] [Related]
5. Activated HIF1α of tumor cells promotes chemoresistance development via recruiting GDF15-producing tumor-associated macrophages in gastric cancer.
Yu S; Li Q; Yu Y; Cui Y; Li W; Liu T; Liu F
Cancer Immunol Immunother; 2020 Oct; 69(10):1973-1987. PubMed ID: 32388677
[TBL] [Abstract][Full Text] [Related]
6. Exosome-mediated communication between gastric cancer cells and macrophages: implications for tumor microenvironment.
Qiu Y; Lu G; Li N; Hu Y; Tan H; Jiang C
Front Immunol; 2024; 15():1327281. PubMed ID: 38455041
[TBL] [Abstract][Full Text] [Related]
7. Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.
Evrard D; Szturz P; Tijeras-Raballand A; Astorgues-Xerri L; Abitbol C; Paradis V; Raymond E; Albert S; Barry B; Faivre S
Oral Oncol; 2019 Jan; 88():29-38. PubMed ID: 30616794
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis inhibitors in early development for gastric cancer.
Pinto MP; Owen GI; Retamal I; Garrido M
Expert Opin Investig Drugs; 2017 Sep; 26(9):1007-1017. PubMed ID: 28770623
[TBL] [Abstract][Full Text] [Related]
9. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials.
Shan F; Miao R; Xue K; Li Z; Li Z; Bu Z; Wu A; Zhang L; Wu X; Zong X; Wang X; Li S; Ji X; Jia Z; Li Z; Ji J
Cancer Lett; 2016 Oct; 380(2):598-607. PubMed ID: 26724681
[TBL] [Abstract][Full Text] [Related]
10. Tumor promoting role of anti-tumor macrophages in tumor microenvironment.
Goswami KK; Ghosh T; Ghosh S; Sarkar M; Bose A; Baral R
Cell Immunol; 2017 Jun; 316():1-10. PubMed ID: 28433198
[TBL] [Abstract][Full Text] [Related]
11. Research progress on tumour‑associated macrophages in gastric cancer (Review).
Zhou Z; Yang Z; Wang J; Wang Q; Zhang H; Ju X
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649792
[TBL] [Abstract][Full Text] [Related]
12. The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.
Zhu C; Kros JM; Cheng C; Mustafa D
Neuro Oncol; 2017 Oct; 19(11):1435-1446. PubMed ID: 28575312
[TBL] [Abstract][Full Text] [Related]
13. M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma.
Jarosz-Biej M; Kamińska N; Matuszczak S; Cichoń T; Pamuła-Piłat J; Czapla J; Smolarczyk R; Skwarzyńska D; Kulik K; Szala S
PLoS One; 2018; 13(1):e0191012. PubMed ID: 29320562
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral Immune Response to Gastric Cancer Varies by Molecular and Histologic Subtype.
Kim TS; da Silva E; Coit DG; Tang LH
Am J Surg Pathol; 2019 Jun; 43(6):851-860. PubMed ID: 30969179
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of the Colorectal Tumor Stroma.
Fridman WH; Miller I; Sautès-Fridman C; Byrne AT
Gastroenterology; 2020 Jan; 158(2):303-321. PubMed ID: 31622621
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer.
Min AKT; Mimura K; Nakajima S; Okayama H; Saito K; Sakamoto W; Fujita S; Endo H; Saito M; Saze Z; Momma T; Ohki S; Kono K
Cancer Immunol Immunother; 2021 Feb; 70(2):289-298. PubMed ID: 32705303
[TBL] [Abstract][Full Text] [Related]
17. Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors.
Kes MMG; Van den Bossche J; Griffioen AW; Huijbers EJM
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188427. PubMed ID: 32961257
[TBL] [Abstract][Full Text] [Related]
18. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors.
Choo YW; Kang M; Kim HY; Han J; Kang S; Lee JR; Jeong GJ; Kwon SP; Song SY; Go S; Jung M; Hong J; Kim BS
ACS Nano; 2018 Sep; 12(9):8977-8993. PubMed ID: 30133260
[TBL] [Abstract][Full Text] [Related]
19. Elevated TUBA1A Might Indicate the Clinical Outcomes of Patients with Gastric Cancer, Being Associated with the Infiltration of Macrophages in the Tumor Immune Microenvironment.
Wang D; Jiao Z; Ji Y; Zhang S
J Gastrointestin Liver Dis; 2020 Dec; 29(4):509-522. PubMed ID: 33331338
[TBL] [Abstract][Full Text] [Related]
20. The Role of Tumor Associated Macrophages (TAMs) in Cancer Progression, Chemoresistance, Angiogenesis and Metastasis - Current Status.
Dallavalasa S; Beeraka NM; Basavaraju CG; Tulimilli SV; Sadhu SP; Rajesh K; Aliev G; Madhunapantula SV
Curr Med Chem; 2021; 28(39):8203-8236. PubMed ID: 34303328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
